Drug Profile
Research programme: glycogen synthase kinase 3 beta inhibitors - Actuate Therapeutics
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Northwestern University; University of Illinois at Chicago
- Developer Actuate Therapeutics; Northwestern University; University of Illinois at Chicago
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Inflammation
Highest Development Phases
- No development reported Breast cancer; Glioblastoma; Inflammation; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 28 Feb 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA
- 28 Feb 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA